Skip to main content
. 2020 Sep 7;10:14713. doi: 10.1038/s41598-020-71715-2

Table 4.

Summary of previous reports on the treatment results of stereotactic radiotherapy for localized prostate cancer.

Study Year, design N Median age, years Median PSA, ng/mL Risk group Median prostate volume, cc Dose (Gy)/fractions Median f/u, M BCRFSb (%) Late toxicity (%)
GI/GU G2 G3 G4
Aluwini13 2013, P 50 68a 8.2a L, I 48a 38 and 44 (DIL)/4 23 2Y, 100 (L, I) GI 3 0 0
GU 10 6 0
Freeman8 2011, P 41 66 5.6 L NA 35–36.25/5 60 5Y, 93 GI 2.5 0 0
GU 7 2.5 0
Katz9 2014, R 515 69.5 5.4 L, I, H 59.15 35–36.25/5 72 7Y, 95.8 (L), 89.3 (I), 68.5 (H) GI 4 0 0
GU 9.1 1.7 0
Davis10 2015, R 437 69 5.8 L, I, H 52 35–38/5 20 2Y, 99 (L), 94.5 (I), 89.8 (H) GI 2 0 0
GU 2–8 0 0
Hannan11 2016, P 91 66 5.4 L, I 33 45–50/5 54 5Y, 90.9 (45 Gy), 100 (47.5–50 Gy) GI 13.2 4.4 2.2
GU 20.9 4.4 1.1
Kishan12 2019, R 2,142 68 5.7 L, I NA 33.5–40/4–5 83 7Y, 95.5 (L), 89.8 (I) GI 4.5 0.4
GU 12.3 2.4

BCRFS biochemical recurrence-free survival, DIL dominant intraprostatic lesion, f/u follow-up, G grade, GI gastrointestinal, GU genitourinary, H high, I intermediate, L low, M months, N numbers, NA not available, P prospective, PSA prostate specific antigen, R retrospective, Y year(s).

aReported as mean values.

bBiochemical recurrence was defined according to Phoenix definition (nadir + 2 ng/mL) in all studies.